GeneDx Holdings Corp
NASDAQ:WGS
Intrinsic Value
GeneDx Holdings Corp. is a patient centered health intelligence company. [ Read More ]
The intrinsic value of one WGS stock under the Base Case scenario is 13.66 USD. Compared to the current market price of 21.16 USD, GeneDx Holdings Corp is Overvalued by 35%.
Valuation Backtest
GeneDx Holdings Corp
Run backtest to discover the historical profit from buying and selling WGS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
GeneDx Holdings Corp
Current Assets | 163.4m |
Cash & Short-Term Investments | 112.9m |
Receivables | 28.9m |
Other Current Assets | 21.6m |
Non-Current Assets | 231.1m |
PP&E | 57.6m |
Intangibles | 169.1m |
Other Non-Current Assets | 4.4m |
Current Liabilities | 50.7m |
Accounts Payable | 9.5m |
Accrued Liabilities | 38.3m |
Other Current Liabilities | 2.9m |
Non-Current Liabilities | 136.6m |
Long-Term Debt | 52.3m |
Other Non-Current Liabilities | 84.3m |
Earnings Waterfall
GeneDx Holdings Corp
Revenue
|
221.9m
USD
|
Cost of Revenue
|
-109.7m
USD
|
Gross Profit
|
112.2m
USD
|
Operating Expenses
|
-237.8m
USD
|
Operating Income
|
-125.6m
USD
|
Other Expenses
|
-9.4m
USD
|
Net Income
|
-135m
USD
|
Free Cash Flow Analysis
GeneDx Holdings Corp
WGS Profitability Score
Profitability Due Diligence
GeneDx Holdings Corp's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
GeneDx Holdings Corp's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
WGS Solvency Score
Solvency Due Diligence
GeneDx Holdings Corp's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
GeneDx Holdings Corp's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
WGS Price Targets Summary
GeneDx Holdings Corp
According to Wall Street analysts, the average 1-year price target for WGS is 15.56 USD with a low forecast of 5.56 USD and a high forecast of 25.2 USD.
Ownership
WGS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
WGS Price
GeneDx Holdings Corp
Average Annual Return | -47.25% |
Standard Deviation of Annual Returns | 52.55% |
Max Drawdown | -100% |
Market Capitalization | 552.7m USD |
Shares Outstanding | 25 978 863 |
Percentage of Shares Shorted | 12.75% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
GeneDx Holdings Corp. is a patient centered health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,200 full-time employees. The company went IPO on 2020-09-04. The firm is engaged in accelerating the use of genomic and clinical information to enable precision medicine as the standard of care. The firm is also engaged in transforming healthcare through its exome and genome testing and interpretation, fueled by rare disease data sets. Its health information platform, Centrellis, which integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data. Its products and services include Exome & genome testing, Test catalog and Genetic counseling. The company offers two types of tests that examine a patient’s deoxyribonucleic acid (DNA), which include genome sequencing (GS/WGS) and exome sequencing (ES/WES). The company offers tests for neurodevelopmental disorders, cardiology, oncology and others.
Contact
IPO
Employees
Officers
The intrinsic value of one WGS stock under the Base Case scenario is 13.66 USD.
Compared to the current market price of 21.16 USD, GeneDx Holdings Corp is Overvalued by 35%.